Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Down 11.1% – Should You Sell?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)’s share price dropped 11.1% during trading on Thursday . The company traded as low as $0.26 and last traded at $0.26. Approximately 72,709,392 shares traded hands during trading, a decline of 5% from the average daily volume of 76,777,180 shares. The stock had previously closed at $0.29.

Wall Street Analyst Weigh In

Separately, StockNews.com started coverage on shares of Tonix Pharmaceuticals in a research report on Thursday. They set a “hold” rating on the stock.

Tonix Pharmaceuticals Price Performance

The company has a 50 day moving average of $0.25 and a 200 day moving average of $0.33. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.81 and a current ratio of 3.33. The stock has a market capitalization of $52.09 million, a price-to-earnings ratio of -0.01 and a beta of 2.02.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) EPS for the quarter, topping analysts’ consensus estimates of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. The business had revenue of $2.82 million during the quarter, compared to the consensus estimate of $2.63 million. As a group, equities research analysts anticipate that Tonix Pharmaceuticals Holding Corp. will post -17.63 EPS for the current year.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.